BARACHO, Nilo César do Vale et al. Bioequivalence study of four different trademarks of enalapril maleate in spontaneously hypertensive rats. Acta Cir. Bras. [online].
2008,
vol.23, n.2, pp. 173-178.
ISSN 1678-2674.
http://dx.doi.org/10.1590/S0102-86502008000200010.
|
|
2. Sociedade Brasileira de Cardiologia, Sociedade Brasileira de Hipertensão, Sociedade Brasileira de Nefrologia. V. Diretrizes brasileiras de hipertensão arterial. São Paulo: SBC; 2006. [ Links ] 3. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289(19):2560-72. [ Links ] 4. Lotufo PA. Stroke in Brazil: a neglected disease. Sao Paulo Med J. 2005;123(1):3-4. [ Links ] 5. Dias CR, Romano-Lieber NS. Generic drug policy implementation in Brazil. Cad Saude Publica. 2006;22(8):1661-9. [ Links ] 6. Nightingale SL, Morrison JC. Generic drugs and the prescribing physician. JAMA. 1987 Sep 4;258(9):1200-4. [ Links ] 7. Chow SC, Liu J. Meta-analysis for bioequivalence review. J Biopharm Stat. 1997 Mar;7(1):97-111. [ Links ] 8. Rodriguez-Iturbe B, Quiroz Y, Ferrebuz A, Parra G, Vaziri ND. Evolution of renal interstitial inflammation and NF-kappaB activation in spontaneously hypertensive rats. Am J Nephrol. 2004;24(6):587-94. [ Links ] 9. Zatz R. A low cost tail-cuff method for the estimation of mean arterial pressure in conscious rats. Lab Anim Sci. 1990;40(2):198-201. [ Links ] 10. Kubota Y, Umegaki K, Kagota S, Tanaka N, Nakamura K, Kunitomo M, Shinozuka K. Evaluation of blood pressure measured by tail-cuff methods (without heating) in spontaneously hypertensive rats. Biol Pharm Bull. 2006;29(8):1756-8. [ Links ] 11. Zintzaras E. Statistical aspects of bioequivalence testing between two medicinal products. Eur J Drug Metab Pharmacokinet. 2005;30(1-2):41-6. [ Links ] 12. Dighe SV. A review of the safety of generic drugs. Transplant Proc. 1999;31 (Suppl 3A): S23-24. [ Links ] 13. Verbeeck RK, Kanfer I, Walker RB. Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy. Eur J Pharm Sci. 2006;28(1-2):1-6. [ Links ] 14. Carmo GC, Martins FS, Quental DP, Santana GSM, Moraes MO, Moraes MEA, Frota Bezerra FA, Nucci G. Bioequivalência de duas formulações de azitromicina. In: XXXIV Congresso Brasileiro de Farmacologia e Terapêutica Experimental; 2002; Águas de Lindóia, São Paulo. Sociedade Brasileira de Farmacologia e Terapêutica Experimental; 2002. p.219. [ Links ] 15. Mendes GD, Araujo MVF, Paris EG, Barrientos-Astigarraga RE, Oliveira CH. Biodisponibilidade comparativa de duas formulações de sertralina em voluntários humanos sadios após a administração de uma única dose. Rev Bras Med. 2004; 61(1/2):80-4. [ Links ] 16. Mendes GEF, Burdmann EA. Comparação da nefrotoxicidade experimental de duas formulações de microemulsão de ciclosporina A. J Bras Nefrol. 2002; 24(Supl 1): S18-25. [ Links ] 17. Borgheini G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther. 2003;25(6):1578-92. [ Links ] |